熱門資訊> 正文
Exact Sciences撤回了对Pholuard竞争对手的禁令请求
2025-08-22 21:43
- 精密科學(EXAS) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Exact Sciences (NASDAQ:EXAS) has withdrawn its request for a preliminary injunction tied to Geneoscopy's patent for its stool-based colorectal cancer screening test, ColoSense, a rival to Cologuard.
- The motion, filed in July 2024, had aimed to block the launch and marketing of ColoSense.
- According to Geneoscopy, the decision to pull back the motion aligns with its view that the injunction request was unfounded.
- With the matter no longer pending, Geneoscopy said it remains free to broaden access to ColoSense for patients and healthcare providers nationwide.
More on Exact Sciences
- Exact Sciences Corporation 2025 Q2 - Results - Earnings Call Presentation
- Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript
- Exact Sciences: Consistent Sales Growth, Stretched Valuation
- Exact Sciences signs exclusive deal with biotech firm Freenome
- Exact Sciences Q2 2025 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
